Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Ji Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1898-0409; OpenAlex author ID A5101605421. Sources: OpenAlex.

Their work

Papers
22 (first author 2, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
51
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: none · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 5 papers · 2022: 3 papers · 2023: none · 2024: 1 paper

Papers 22

  1. Recurrence scoring system predicting early recurrence for patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy and portomesenteric vein res… Co-author DOI 10.4240/wjgs.v16.i10.3185↗
  2. High Glucose Promotes Pancreatic Ductal Adenocarcinoma Gemcitabine Resistance and Invasion through Modulating ROS/MMP-3 Signaling Pathway. Last author DOI 10.1155/2022/3243647↗
  3. The expression and survival significance of sodium glucose transporters in pancreatic cancer. Last author DOI 10.1186/s12885-021-09060-4↗
  4. The Intricate Crosstalk Between Insulin and Pancreatic Ductal Adenocarcinoma: A Review From Clinical to Molecular. Co-author DOI 10.3389/fcell.2022.844028↗
  5. Basal microvilli define the metabolic capacity and lethal phenotype of pancreatic cancer. Co-author DOI 10.1002/path.5588↗
  6. The Expression and Survival Significance of Glucose Transporter-1 in Pancreatic Cancer: Meta-Analysis, Bioinformatics Analysis and Retrospective Study. Last author DOI 10.1080/07357907.2021.1950755↗
  7. An immune-related lncRNA signature for the prognosis of pancreatic adenocarcinoma. Co-author DOI 10.18632/aging.203323↗
  8. Identification of the Real Hub Gene and Construction of a Novel Prognostic Signature for Pancreatic Adenocarcinoma Based on the Weighted Gene Co-expression Net… Co-author DOI 10.3389/fgene.2021.692953↗
  9. Liver-Metastasis-Related Genes are Potential Biomarkers for Predicting the Clinical Outcomes of Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.3389/pore.2021.1609822↗
  10. Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels. Last author DOI 10.1042/bsr20200401↗
  11. Blood-based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Pancreatic Cancer and its Value to Guide Clinical Treatment. Co-author DOI 10.7150/jca.43087↗
  12. Pancreatoduodenectomy with portal vein resection favors the survival time of patients with pancreatic ductal adenocarcinoma: A propensity score matching analys… First author DOI 10.3892/ol.2019.10822↗
  13. Stroma - A Double-Edged Sword in Pancreatic Cancer: A Lesson From Targeting Stroma in Pancreatic Cancer With Hedgehog Signaling Inhibitors. Last author DOI 10.1097/mpa.0000000000001023↗
  14. Dynamic quantitative detection of ABC transporter family promoter methylation by MS-HRM for predicting MDR in pancreatic cancer. Last author DOI 10.3892/ol.2018.8041↗
  15. Orphan nuclear receptor Nurr1 as a potential novel marker for progression in human pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/etm.2016.3968↗
  16. Process of hepatic metastasis from pancreatic cancer: biology with clinical significance. First author DOI 10.1007/s00432-015-2024-0↗
  17. Application of Deuteporfin in the Metastatic Lymph Node Mapping of Pancreatic Cancer: An in vivo Study. Last author DOI 10.1111/php.12574↗
  18. NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s11010-015-2535-7↗
  19. High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1007/s13277-015-3625-6↗
  20. Research on the relationships between pancreatic cancer and hyperglycemia in Chinese populations. Co-author DOI 10.1111/j.2040-1124.2012.00237.x↗
  21. The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer. Co-author DOI 10.3892/or.2013.2516↗
  22. Increased COMT expression in pancreatic cancer and correlation with clinicopathologic parameters. Last author DOI 10.1007/s11427-012-4375-y↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Deliang Fu · 12 shared papers, 2013–2024 · strength 1.53
  2. Jichun Gu · 10 shared papers, 2018–2022 · strength 1.35
  3. Chen Jin · 7 shared papers, 2013–2024 · strength 0.81
  4. Jiali Du · 5 shared papers, 2020–2022 · strength 0.79
  5. Junyuan Deng · 4 shared papers, 2021–2022 · strength 0.61
  6. Lei Kong · 4 shared papers, 2021–2022 · strength 0.61
  7. Hang He · 4 shared papers, 2013–2024 · strength 0.42
  8. Yongjian Jiang · 3 shared papers, 2013–2024 · strength 0.36
  9. Lie Yao · 4 shared papers, 2013–2020 · strength 0.28
  10. Feng Yang · 2 shared papers, 2013–2024 · strength 0.26
  11. Hexige Saiyin · 2 shared papers, 2018–2021 · strength 0.26
  12. Deliang Fu · 3 shared papers, 2013–2022 · strength 0.25
  13. Guoxiong Zhou · 3 shared papers, 2015–2017 · strength 0.16
  14. Yinlei Dong · 1 shared paper, 2021 · strength 0.16
  15. Qihang Yuan · 1 shared paper, 2021 · strength 0.16
  16. Zhizhou Wang · 1 shared paper, 2021 · strength 0.16
  17. Dawei Deng · 1 shared paper, 2021 · strength 0.16
  18. Dong Shang · 1 shared paper, 2021 · strength 0.16
  19. Baian Tao · 1 shared paper, 2022 · strength 0.15
  20. Wenhui Lou · 1 shared paper, 2021 · strength 0.14
  21. Lixiang Ma · 1 shared paper, 2021 · strength 0.14
  22. Xu Han · 1 shared paper, 2021 · strength 0.14
  23. Dansong Wang · 1 shared paper, 2021 · strength 0.14
  24. Qi Zhou · 1 shared paper, 2021 · strength 0.13
  25. Bing Qi · 1 shared paper, 2021 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.